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Syntheses of a library of molecules on the marine
natural product ianthelliformisamines platform
and their biological evaluation†
Faiz Ahmed Khan,*a Saeed Ahmad,a Naveena Kodipelli,b Gururaj Shivangeb and
Roy Anindya*b
Ianthelliformisamines A–C are a novel class of bromotyrosine-derived antibacterial agents isolated
recently from the marine sponge Suberea ianthelliformis. We have synthesized ianthelliformisamines A–C
straightforwardly by the condensation of (E)-3-(3,5-dibromo-4-methoxyphenyl)acrylic acid and the
corresponding Boc-protected polyamine followed by Boc-deprotection with TFA. Further, using this
reaction protocol, a library of their analogues (39 analogues) has been synthesized by employing
3-phenylacrylic acid derivatives and Boc-protected polyamine chains through various combinations of
these two fragments diﬀering in phenyl ring substitution, double bond geometry or chain length of the
central spacer of the polyamine chain (shown in red color). All the synthesized compounds (ianthelliformi-
samines A–C and their analogues) were screened for antibacterial activity against both Gram-negative
(Escherichia coli) and Gram-positive (Staphylococcus aureus) strains. All synthetic analogues of ianthelli-
formisamine A showed bacterial growth inhibition against both strains (Escherichia coli and Staphylococ-
cus aureus), having MIC values in the range of 117.8–0.10 μM, while none of the synthetic analogues of
ianthelliformisamine C as well as the parent compound showed any detectable antibacterial activity. Inter-
estingly, some of the synthetic analogues of ianthelliformisamines A and B exerted a bactericidal eﬀect
against both E. coli and S. aureus strains, decreasing viable bacterial count by 99% at concentrations as
low as 2 × MIC.
Introduction
The emergence of antibiotic resistant bacterial pathogens is a
major public health concern worldwide and it has highlighted
the need for the development of new antibiotics. Unfortu-
nately, there have been only a few new classes of clinically
important antibiotics discovered in recent years, emphasizing
the need to develop antibiotics possessing new scaﬀolds with
novel modes of action.1 Natural and artificial polyamines oﬀer
a promising new group of antibacterial compounds and have
been shown to increase the susceptibility of bacteria to several
antibiotics.2 Natural polyamines, like spermine and spermi-
dine, are found in significant amounts in all organisms
ranging from prokaryotic to eukaryotic cells and are con-
sidered as cell growth factors.3,4 In bacteria, they regulate key
cellular processes like DNA replication, transcription, and
translation and influence the optimal cell growth and viability
by protecting from various toxic conditions, e.g., radiation,
acidic pH, and oxidative stress.5–11 Polyamine analogues, in
contrast, completely lack any physiological function but, being
structurally similar to natural polyamines, act as decoys and
compete with natural polyamines, and aﬀect major cellular
processes. Not surprisingly, polyamine analogues were develo-
ped as potential antibiotics in treating several parasitic
diseases.12–18
Natural medicinal ingredients have been used by mankind
for thousands of years for the treatment of various diseases
and ailments, and also in the current paradigm, isolated
natural products have proven a rich source of potent biological
activities in all therapeutic areas.19–21 In the past few decades,
natural products have remarkably influenced the area of drugs
development. According to a report, in the last 30 years during
the period 1981–2010, approximately half of the drugs
approved by the US Food and Drug Administration (FDA) or by
similar organizations are actually either natural products or
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their derivatives or molecules designed and synthesized on
natural products platforms.22 In the search for therapeutic
agents against drug-resistant microbes with novel modes of
actions, natural products can be considered as pre-validated
leads and one can reckon on nature’s ability to make biologi-
cally relevant chemical entities.23 Even though many well-
established techniques are available for the isolation and
characterization of natural products, acquisition of new
natural products is still a very tedious and laborious task in
terms of diﬃculties associated with isolation, poor yield and
structure elucidation.24 In this aspect, synthesis of a library
of molecules on the biologically potent natural products
template is one of the worthwhile approaches for finding lead
compounds.25
Recently, Quinn and co-workers isolated bromotyrosine-
derived alkaloids, ianthelliformisamines A–C (1–3, Fig. 1),
from the marine sponge Suberea ianthelliformis.26 Based on
extensive NMR experiments, the structures of ianthelliformis-
amines were assigned as a polyamine chain (spermine or sper-
midine) condensed with (E)-3-(3,5-dibromo-4-methoxyphenyl)-
acrylic acid, forming amide linkage.26 Previously isolated
natural products spermatinamine,27a pseudoceramines A–C27b
and tokaradine C27c also possess the same skeleton and are
represented in Fig. 1 (4–8).
The isolated natural products ianthelliformisamines A–C
(1–3) exhibited antibacterial activity, and out of them, ianthelli-
formisamine A (1) was found most active against the Gram-
negative bacterium Pseudomonas aeruginosa with a MIC value
of 35 μM.26 The profound potent antibacterial activities of
ianthelliformisamines A–C prompted us to design and syn-
thesize a library of molecules on these platforms in order to
explore more potent leads than the original natural products.
We envisaged that bisecting the title molecules into two parts,
viz., a 3-phenylacrylic acid derivative and a polyamine chain,
would provide a convenient handle to create a library through
various combinations of the two parts diﬀering in phenyl ring
substitution, double bond geometry or chain length of the
central spacer of the polyamine chain (shown in red color). For
this purpose, we have used substituted aromatic aldehydes
9a–d and Boc-protected polyamines (12a–c, 13a–c and 14a–c).
Interestingly, the choice of phenyl ring substituents in alde-
hydes 9a–d is inspired by the presence of these moieties
in marine natural products like amathamides,28 wilsoni-
amines,28c convolutamines,29 and amathaspiramides.30
Herein, we report a synthesis of natural products ianthellifor-
misamines A–C and a library built on their platform. All the
synthetic analogues of ianthelliformisamines were screened
for antibacterial activity. Our results revealed a set of synthetic
Fig. 1 Structures of naturally occurring bromotyrosine-derived alkaloids possessing polyamine chains.
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ianthelliformisamine-mimicking analogues exhibiting enhanced
antibacterial activity.
Results and discussion
Chemistry
Ianthelliformisamines A–C (1–3) contain an (E)-3-(3,5-
dibromo-4-methoxyphenyl)acrylic acid moiety which is con-
nected with the polyamine chain spermine or spermidine via
amide functionality. We commenced the preparation of (E)-3-
(3,5-dibromo-4-methoxyphenyl)acrylic acid from 3,5-dibromo-
4-methoxybenzaldehyde 9a which was obtained from 4-hydroxy-
benzaldehyde by using the literature protocol via bromination
with Br2/AcOH/NH4OAc
31a followed by methylation of the
hydroxyl group with MeI.31b To access a library of analogues,
2,4,6-tribromo-3-methoxybenzaldehyde 9b and 2,4-dibromo-5-
methoxybenzaldehyde 9d were prepared from 3-hydroxybenzal-
dehyde by treating it with Br2/H2O
32 and Br2/CHCl3,
32 respecti-
vely, followed by methylation of the hydroxyl group with MeI.32
2,3,4-Tribromo-5-methoxybenzaldehyde 9c is accessible from
Grob-type fragmentation–aromatization reaction of 1,4,5,6-
tetrabromo-7,7-dimethoxybicyclo[2.2.1]-hept-5-en-2-one fol-
lowed by further functional group transformations.33 The alde-
hydes 9a–d were converted into α,β-unsaturated ethyl esters
10a–f by Wittig reaction of ethoxycarbonylmethylenetriphenyl-
phosphorane in THF (Scheme 1).34 We found that aldehydes
9a and 9b gave exclusively trans products in excellent
yields, while other aldehydes 9c and 9d gave a mixture of
chromatographically separable cis and trans products in a ratio
of 1 : 3, respectively. Further, α,β-unsaturated ethyl esters 10a–f
were hydrolyzed by lithium hydroxide monohydrate
(LiOH·H2O)–THF–water
35 to get α,β-unsaturated carboxylic
acids 11a–f (Scheme 1).
Boc-protected spermines 12b and 13b were synthesized
from 1,4-diaminobutane according to the literature protocol36
(Scheme 2). Other Boc-protected spermine analogues (12a, c
and 13a, c) were also synthesized by using the same literature
protocol from the corresponding diamines (Scheme 2).36 In
the reaction sequence, the corresponding diamines (n = 1, 2
and 4) on treatment with acrylonitrile (2.0 equiv.) gave the bis
Michael adduct. Further, central amines were protected with
the Boc-group and then nitrile groups were reduced by
RANEY-Ni® to get Boc-protected amines 12a–c.36a TriBoc-tetra-
amines 13a–c were synthesized from amines 12a–c via a three
step one-pot protocol.36 In the reaction sequence, first, amines
12a–c were predominantly mono-trifluoroacetylated by treat-
ment of ethyl trifluoroacetate at −78 °C and then the remain-
ing amine group was protected with Boc by using Boc2O.
Further, in situ deprotection of the trifluoroacetate group with
K2CO3 under reflux conditions gave triBoc-tertaamines
13a–c.36 Boc-protected spermidine 14b and its analogues 14a,c
were synthesized from the corresponding diamines via selec-
tive mono-Michael addition to acrylonitrile and then Boc-
protection of primary and secondary amines37a followed by
reduction of the nitrile group with LiAlH4.
37b
Coupling of (E)-3-(3,5-dibromo-4-methoxyphenyl)acrylic
acid 11a and (N1,N4,N9-tri-tert-butoxycarbonyl)-1,12-diamino-
Scheme 1 Syntheses of 3-phenylacrylic acid derivatives.
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4,9-diazadodecane 13b by using EDC·HCl as a coupling
reagent38 gave the corresponding amide, which after Boc-
deprotection with trifluoroacetic acid (TFA) in CH2Cl2
38 at
0 °C yielded compound 1 as a TFA salt with 68% yield in 2
steps (Scheme 3). Synthetic 1 was confirmed as ianthelliformis-
amine A (1) by 1H NMR, 13C NMR and high-resolution mass
spectrometry.
Coupling of (E)-3-(3,5-dibromo-4-methoxyphenyl)acrylic
acid 11a and Boc-protected spermidine 14b by using EDC·HCl
as a coupling reagent38 followed by deprotection of the Boc-
group with trifluoroacetic acid38 yielded compound 2 as a TFA
salt with 74% yield in 2 steps (Scheme 3). Synthetic compound
2 has all spectroscopic data in accordance with the literature
reported values of ianthelliformisamine B. Coupling of (E)-3-
(3,5-dibromo-4-methoxyphenyl)acrylic acid 11a and N1,N4-di-
(tert-butyloxycarbonyl)-N1,N4-di(3-aminopropyl)-1,4-butanedi-
amine 12b gave the corresponding amide, which after Boc-
deprotection with trifluoroacetic acid yielded compound 3 as a
Scheme 2 Syntheses of Boc-protected spermine, spermidine and their analogues.
Scheme 3 Synthesis of ianthelliformisamine A (1), ianthelliformisamine B (2) and ianthelliformisamine C (3).
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TFA salt (Scheme 3). Synthetic 3 was confirmed to be identical
to ianthelliformisamine C (3) by NMR (1H and 13C NMR) and
high-resolution mass spectrometry. Further, a library of
ianthelliformisamines A–C analogues 15–53 (a total of 39 ana-
logues, Tables 1–3) were synthesized by employing various
α,β-unsaturated carboxylic acids having diﬀerently substituted
phenyl ring 11a–f and Boc-protected polyamines (spermine,
spermidine and their analogues) (12a–c, 13a–c, 14a–c) using
the same reaction procedure as for ianthelliformisamines A–C.
Antibacterial activity
Synthetic analogues of ianthelliformisamines A–C were evalu-
ated for their in vitro antibacterial activity against representa-
tive Gram-positive (Staphylococcus aureus) and Gram-negative
(Escherichia coli) strains using standard techniques. Minimum
inhibitory concentration (MIC) was defined as the lowest con-
centration that inhibited bacterial growth and started the zone
of inhibition as compared to the control, and MICs of the
Table 1 Antibacterial activities of ianthelliformisamine A (1) and its synthetic analogues
Compd. Structure Yielda (%)
Inhibition zone
diameter against the
microorganismb MIC (μM)
E. coli S. aureus E. coli S. aureus
1 68 ++ ++ 11.04 11.04
15 70 ++ ++ 11.04 11.04
16 73 +++ +++ 1.1 1.6
17 89 +++ +++ 1.2 0.12
18 74 + + 107.8 107.8
19 68 +++ +++ 1.1 1.1
20 71 +++ +++ 1.2 1.2
21 72 +++ + 0.12 117.8
22 82 ++ ++ 11.2 11.2
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Table 1 (Contd.)
Compd. Structure Yielda (%)
Inhibition zone
diameter against the
microorganismb MIC (μM)
E. coli S. aureus E. coli S. aureus
23 80c ++ ++ 10.3 10.3
24 73 +++ +++ 1.03 0.10
25 68d +++ +++ 0.11 0.11
26 66 +++ + 0.11 112
a All reactions were performed at 0.1 or 0.2 mmol scale. Yield in 2 steps. b Eﬀectivity was classified into three zones based on the diameter of
zone of inhibition; +++: most eﬀective; ++: moderately eﬀective; +: slightly eﬀective. cHas a mixture of E and Z isomers (5 : 1). dHas a mixture of E
and Z isomers (9 : 1).
Table 2 Antibacterial activities of ianthelliformisamine B (2) and its synthetic analogues
Compd. Structure Yielda (%)
Inhibition zone
diameter against the
microorganismb MIC (μM)
E. coli S. aureus E. coli S. aureus
2 74 ++ + 14.5 144.7
27 85 + + 129.8 129.8
28 78 + + 129.8 129.8
29 78 + + 129.8 129.8
30 84 ++ + 14.5 144.7
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Table 2 (Contd.)
Compd. Structure Yielda (%)
Inhibition zone
diameter against the
microorganismb MIC (μM)
E. coli S. aureus E. coli S. aureus
31 75 +++ + 1.47 144.7
32 88 +++ +++ 1.47 1.47
33 90 ++ + 13.2 132.2
34 94 ++ + 13.2 132.2
35 83c +++ +++ 0.15 0.15
36 83d +++ — 0.15 1476
37 82 +++ — 1.46 1464
38 66 + + 125.3 125.3
39 63 +++ +++ 1.3 1.3
40 74 — — NA NA
41 77 + + 773.5 773.5
42 79 +++ + 1.39 139
a All reactions were performed at 0.1 or 0.2 mmol scale. Yield in 2 steps. b Eﬀectivity was classified into three zones based on the diameter of
zone of inhibition; +++: most eﬀective; ++: moderately eﬀective; +: slightly eﬀective; —: not eﬀective. NA: no activity. cHas a mixture of E and Z
isomers (18 : 1). dHas a mixture of Z and E isomers (15 : 1).
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Table 3 Antibacterial activities of ianthelliformisamine C (3) and its synthetic analogues
Compd. Structure Yielda (%)
Inhibition zone
diameter against the
microorganismb MIC (μM)
E. coli S. aureus E. coli S. aureus
3 75 — — NA NA
43 85 — — NA NA
44 73 — — NA NA
45 89 — — NA NA
46 88 — — NA NA
47 83 — — NA NA
48 77 — — NA NA
49 81 — — NA NA
50 84 — — NA NA
51 81 — — NA NA
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synthesized compounds are reported in Tables 1–3 and ESI
Fig. A.† These compounds did not belong to the PAINS (pan
assay interference compounds) category.39
The results indicate that in comparison with the natural
product ianthelliformisamine A (1), when the phenyl ring is
substituted with 2,3,4-tribromo-5-methoxy (compd. 15,
Table 1), there was no change in antibacterial activity, while
when the phenyl ring is substituted with 2,4,6-tribromo-5-
methoxy (compd. 16, Table 1), antibacterial activity increased
up to 10-fold in both strains. After decreasing the middle
carbon chain of spermine from four to three (represented in
red color) antibacterial activity increased up to 10-fold in E.
coli and up to 100-fold in S. aureus (compd. 17, Table 1), while
by increasing the middle carbon chain of spermine from four
to six there was no eﬀect on antibacterial activity (compd. 22,
Table 1). In conclusion, cis analogues are more or equally
active in E. coli, but less active in S. aureus in comparison with
their trans counterparts (compd. 20, 21 and 25, 26, Table 1).
Among the synthetic analogues of ianthelliformisamine A,
antibacterial activities of compounds 16, 17, 19, 20 and 24
were found highly potent against both Gram-positive and
Gram-negative bacteria with MIC value less than 2 μM. In par-
ticular, compound 25 (MIC value 0.11 μM, against both E. coli
and S. aureus) was found to be the most potent antibacterial
agent in this series and has 100-fold less MIC value than the
parent compound ianthelliformisamine A (1) (MIC value
11.04 μM, against both E. coli and S. aureus) (Table 1).
In the series of ianthelliformisamine B (2) analogues, on
changing the substituents on the phenyl ring, antibacterial
activity slightly changed in E. coli, but there was no change of
antibacterial activity in S. aureus (compd. 27–31, Table 2). In
comparison with ianthelliformisamine B (2), on decreasing
the terminal carbon chain of spermidine from four to three
(represented in red color), antibacterial activity increased up to
10-fold in E. coli and 100-fold in S. aureus (compd. 32,
Table 2), while on increasing the terminal carbon chain of
spermidine from four to six, antibacterial activity increased
10-fold in E. coli and decreased 10-fold in S. aureus (compd.
37, Table 2). Among the synthetic analogues of ianthelliformi-
samine B (2), compounds 32, 35 and 39 (MIC values 1.47, 0.15
and 1.3 μM, respectively, against both E. coli and S. aureus)
were found to be far better than the parent compound, ianthel-
liformisamine B (2) (MIC values 14.5 and 144.7 μM against
E. coli and S. aureus, respectively) (Table 2). In this series the
most eﬃcient synthetic analogue is 35 (MIC values 0.15 μM in
both strains). In the series of synthetic analogues of ianthelli-
formisamines A and B, our finding was that substituted
phenyl rings as well as polyamines are both equally respon-
sible for antibacterial activity. Unfortunately, the series of
ianthelliformisamine C analogues (compd. 43–53) as well as
parent compound 3 did not show any significant antibacterial
activity against both E. coli and S. aureus (Table 3), and there
was no eﬀect of substituted phenyl rings, size of polyamine
chains and double bond geometry.
To further investigate the antibiotic activity, we conducted
time-kill assays where cultures of E. coli and S. aureus were
exposed to the test compounds and at subsequent times
samples were recovered, diluted and plated for counting to
diﬀerentiate between bacteriostatic and bactericidal eﬀects.
Interestingly, among the ianthelliformisamine A (1) analogues,
compounds 15, 18, 20, 23, and among the ianthelliformisamine
B (2) analogues, compounds 33, 34, 38 exerted a bactericidal
eﬀect against E. coli and S. aureus reducing viable bacterial cfu
by 99% within 4 h at concentrations as low as 2 × MIC (ESI
Fig. B†). Ianthelliformisamine A (1) analogues, compounds 22,
24, 25, and ianthelliformisamine B (2) analogues, compounds
27, 28, 41, showed bactericidal activity against Gram-negative
E. coli but partial activity to Gram-positive S. aureus.
Table 3 (Contd.)
Compd. Structure Yielda (%)
Inhibition zone
diameter against the
microorganismb MIC (μM)
E. coli S. aureus E. coli S. aureus
52 87 — — NA NA
53 88 — — NA NA
a All reactions were performed at 0.1 or 0.2 mmol scale. Yield in 2 steps. b Eﬀectivity was classified into zones based on the diameter of zone of
inhibition;—: not eﬀective; NA: no activity.
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Conclusion
In conclusion, we have synthesized natural products ianthelli-
formisamines A–C by condensation of (E)-3-(3,5-dibromo-4-
methoxyphenyl)acrylic acid and Boc-protected polyamine
(spermine or spermidine) followed by Boc-deprotection with
TFA. Further, a variety of synthetic analogues (39 analogues) of
ianthelliformisamines A–C, varying in substitution on the
phenyl ring, size of the polyamine chain and double bond geo-
metry, were prepared by using 3-phenylacrylic acid derivatives
and Boc-protected polyamines (spermine, spermidine and
their analogues). All the synthesized compounds (ianthelli-
formisamines A–C and their 39 synthetic analogues) were
screened for antibacterial activity. In the series of analogues of
ianthelliformisamines A and B, the change in the substitution
of the phenyl ring as well as the change in the size of poly-
amine chains are both equally responsible for antibacterial
activity. Our results revealed that synthetic analogues of
ianthelliformisamines A and B are more potent against both
Gram-negative and Gram-positive bacteria than the parent natural
products.
Experimental section
General methods
All reactions were performed in oven dried apparatus and
under an argon atmosphere. Commercial grade solvents were
distilled before use. Melting points were obtained in open
capillary tubes and are uncorrected. 1H NMR spectra were
recorded at 400 MHz or 500 MHz and proton decoupled 13C
NMR spectra were recorded at 100 MHz or 125 MHz. Infrared
spectra were recorded as KBr pellets or as thin films. High-
resolution mass spectra (HRMS) were recorded using electron
spray ionization (ESI) or atmospheric pressure chemical ioniza-
tion (APCI) mode. The purity of all compounds (1–3 and
15–53), tested for biological activity, was determined by high-
pressure liquid chromatography (HPLC) and it was found
>95% pure. The HPLC method utilized for purity: Waters
HPLC with C18 column (5.0 μm, 4.6 × 250 mm2); flow rate =
0.1 mL min−1; solvent 0.1% TFA–MeOH; pressure 135–140 psi;
wavelength 254 nm.
General experimental procedure for the preparation of 10a–f
by Wittig reaction
To a cooled (0 °C) solution of ethoxycarbonylmethylenetri-
phenylphosphorane (Ph3PCHCO2Et, 1.1 mmol, 1.1 equiv.) in
THF (4 mL) was added an appropriate aromatic aldehyde
(1.0 mmol, 1.0 equiv.) and then it was allowed to warm to
room temperature with stirring. After complete consumption
of the starting material (monitored by TLC), all volatiles were
removed under reduced pressure, and the residue was purified
by silica gel column chromatography (3–8% EtOAc–hexane) to
get the Wittig products 10a–f.
(E)-Ethyl 3-(3,5-dibromo-4-methoxyphenyl)acrylate (10a).
The product was obtained as a white solid (1.84 g, 99%); Mp
139–141 °C; 1H NMR (500 MHz, CDCl3) δ 7.65 (s, 2H), 7.48 (d,
1H, J = 15.9 Hz), 6.34 (d, 1H, J = 16.2 Hz), 4.25 (q, 2H, J =
7.2 Hz), 3.90 (s, 3H), 1.32 (t, 3H, J = 7.2 Hz); 13C NMR
(125 MHz, CDCl3) δ 166.3, 155.5, 141.0, 133.2, 132.0, 120.2,
118.8, 60.9, 14.3; IR (KBr) 3065, 2977, 1719, 1638, 1476, 1175,
991, 855 cm−1; HRMS (ESI) calcd for C12H13Br2O3 (M + H),
362.9231; found, 362.9238.
(E)-Ethyl 3-(2,4,6-tribromo-3-methoxyphenyl)acrylate (10b).
The product was obtained as a white solid (2.27 g, 96%); Mp
83–85 °C; 1H NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.56 (d,
1H, J = 16.3 Hz), 6.35 (d, 1H, J = 16.3 Hz), 4.30 (q, 2H, J =
7.1 Hz), 3.88 (s, 3H), 1.36 (t, 3H, J = 7.1 Hz); 13C NMR
(100 MHz, CDCl3) δ 165.7, 154.2, 141.7, 136.6, 136.0, 127.4,
120.3, 118.3, 118.1, 61.0, 60.6, 14.3; IR (neat) 3068, 2934, 1719,
1644, 1449, 1268, 1171, 938, 744 cm−1; HRMS (APCI) calcd for
C12H12Br3O3 (M + H), 440.8337; found, 440.8333.
(Z)-Ethyl 3-(2,3,4-tribromo-5-methoxyphenyl)acrylate (10c)
and (E)-ethyl 3-(2,3,4-tribromo-5-methoxyphenyl)acrylate
(10d). After column purification Z-product 10c was obtained
as a white puﬀy solid (0.58 g, 24%) and E-product 10d was
obtained as a white crystalline solid (1.74 g, 73%). Data for
Z-product 10c: Mp 132–134 °C; 1H NMR (400 MHz, CDCl3)
δ 7.05 (s, 1H), 7.01 (d, 1H, J = 12.2 Hz), 6.06 (d, 1H, J =
12.2 Hz), 4.11 (q, 2H, J = 7.1 Hz), 3.87 (s, 3H), 1.20 (t, 3H, J =
7.1 Hz); 13C NMR (100 MHz, CDCl3) δ 165.1, 155.5, 142.8,
137.0, 129.0, 122.2, 116.7, 116.2, 112.5, 60.6, 56.9, 14.1; IR
(neat) 2979, 1716, 1530, 1364, 1203, 1063, 864 cm−1; HRMS
(ESI) calcd for C12H12Br3O3 (M + H), 440.8337; found,
440.8350. Data for E-product 10d: Mp 162–164 °C; 1H NMR
(400 MHz, CDCl3) δ 7.98 (d, 1H, J = 15.8 Hz), 6.99 (s, 1H), 6.31
(d, 1H, J = 15.8 Hz), 4.27 (q, 2H, J = 7.1 Hz), 3.91 (s, 3H), 1.33
(t, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 165.9, 156.2,
144.0, 136.1, 130.4, 122.5, 119.0, 118.1, 108.6, 61.0, 56.9, 14.3;
IR (neat) 2981, 1714, 1634, 1410, 1187, 1069, 965, 837 cm−1;
HRMS (ESI) calcd for C12H12Br3O3 (M + H), 440.8337; found,
440.8331.
(Z)-Ethyl 3-(2,4-dibromo-5-methoxyphenyl)acrylate (10e) and
(E)-ethyl 3-(2,4-dibromo-5-methoxyphenyl)acrylate (10f). After
column purification Z-product 10e was obtained as a white
solid (1.29 g, 24%) and E-product 10f was obtained as a white
puﬀy solid (4.02 g, 74%). Data for Z-product 10e: Mp 83–85 °C;
1H NMR (400 MHz, CDCl3) δ 7.73 (s, 1H), 7.21 (s, 1H), 6.99 (d,
1H, J = 12.3 Hz), 6.08 (d, 1H, J = 12.3 Hz), 4.13 (q, 2H, J =
7.1 Hz), 3.88 (s, 3H), 1.21 (t, 3H, J = 7.2 Hz); 13C NMR
(100 MHz, CDCl3) δ 165.4, 154.7, 141.5, 135.7, 135.4, 122.2,
114.2, 114.0, 112.7, 60.5, 56.5, 14.1; IR (neat) 2981, 2849, 1713,
1469, 1369, 1189, 1039, 874 cm−1; HRMS (ESI) calcd for
C12H13Br2O3 (M + H), 362.9231; found, 362.9210. Data for
E-product 10f: Mp 141–143 °C; 1H NMR (400 MHz, CDCl3) δ
7.93 (d, 1H, J = 15.8 Hz), 7.77 (s, 1H), 7.06 (s, 1H), 6.39 (d, 1H,
J = 16.0 Hz), 4.29 (q, 2H, J = 7.1 Hz), 3.92 (s, 3H), 1.35 (t, 3H,
J = 7.1 Hz); 13C NMR (100 MHz, CDCl3) δ 166.1, 155.5, 142.3,
136.9, 134.4, 121.4, 116.0, 114.6, 109.9, 60.9, 56.5, 14.3; IR
(neat) 2979, 2899, 1706, 1369, 1233, 1041, 871 cm−1; HRMS
(APCI) calcd for C12H13Br2O3 (M + H), 362.9231; found,
362.9243.
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General experimental procedure for alkaline hydrolysis of
ethylesters 10a–f. Preparation of compounds 11a–f
To a cooled (0 °C) solution of an appropriate α,β-unsaturated
ethyl ester (1.0 mmol, 1.0 equiv.) in THF–H2O (5 mL : 1 mL)
was added lithium hydroxide monohydrate (LiOH·H2O,
1.5 mmol, 1.5 equiv.) and then it was allowed to warm to room
temperature with stirring. After complete consumption of the
starting material (monitored by TLC), all volatiles were
removed under reduced pressure, and the residue was diluted
with water (1 mL) and made acidic up to pH 2–3 with 10%
HCl. The aqueous layer was extracted with EtOAc (4 × 5 mL).
The combined organic layers were washed with brine, dried
over Na2SO4 and concentrated to get the carboxylic acid 11a–f.
(E)-3-(3,5-Dibromo-4-methoxyphenyl)acrylic acid (11a). The
product 11a was obtained as a white puﬀy solid (5.0 g, 98%);
Mp 202–205 °C (decomposed); 1H NMR (400 MHz, DMSO-d6) δ
12.52 (br s, 1H), 8.04 (s, 2H), 7.50 (d, 1H, J = 16.1 Hz), 6.62 (d,
1H, J = 15.6 Hz), 3.81 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ
167.2, 154.4, 140.4, 133.6, 132.3, 121.4, 118.0, 60.5; IR (neat)
2803, 1695, 1631, 1422, 1214, 975, 850, 745 cm−1; HRMS (ESI)
calcd for C10H9Br2O3 (M + H), 334.8918; found, 334.8917.
(E)-3-(2,4,6-Tribromo-3-methoxyphenyl)acrylic acid (11b).
The product 11b was obtained as a white solid (2.66 g, 97%);
Mp 200–203 °C (decomposed); 1H NMR (400 MHz, DMSO-d6) δ
12.90 (br s, 1H), 8.09 (s, 1H), 7.41 (d, 1H, J = 16.2 Hz), 6.26 (d,
1H, J = 16.3 Hz), 3.81 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ
166.3, 153.6, 141.2, 136.6, 135.6, 128.1, 119.8, 117.85, 117.80,
60.3; IR (neat) 2977, 2845, 1691, 1417, 1288, 1037, 873,
741 cm−1; HRMS (ESI) calcd for C10H8Br3O3 (M + H), 412.8024;
found, 412.8018.
(Z)-3-(2,3,4-Tribromo-5-methoxyphenyl)acrylic acid (11c).
The product 11c was obtained as a white solid (0.34 g, 96%);
Mp 250–253 °C (decomposed); 1H NMR (400 MHz, DMSO-d6) δ
12.50 (br s, 1H), 7.18 (s, 1H), 7.04 (d, 1H, J = 11.7 Hz), 6.12 (d,
1H, J = 12.2 Hz), 3.83 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ
166.2, 155.2, 141.0, 138.2, 127.8, 124.0, 115.5, 114.5, 112.9,
57.0; IR (neat) 3051, 2963, 1701, 1632, 1469, 1376, 1235, 1071,
855 cm−1; HRMS (ESI) calcd for C10H8Br3O3 (M + H), 412.8024;
found, 412.8032.
(E)-3-(2,3,4-Tribromo-5-methoxyphenyl)acrylic acid (11d).
The product 11d was obtained as a white solid (1.53 g, 98%);
Mp 250–255 °C (decomposed); 1H NMR (400 MHz, DMSO-d6)
δ 12.75 (br s, 1H), 7.80 (d, 1H, J = 15.8 Hz), 7.48 (s, 1H), 6.72
(d, 1H, J = 15.8 Hz), 3.95 (s, 3H); 13C NMR (100 MHz, DMSO-
d6) δ 166.9, 156.1, 142.3, 135.7, 129.1, 124.4, 117.9, 117.0,
110.1, 57.3; IR (neat) 2807, 1680, 1626, 1455, 1362, 1228, 1065,
940, 727 cm−1; HRMS (ESI) calcd for C10H8Br3O3 (M + H),
412.8024; found, 412.8010.
(Z)-3-(2,4-Dibromo-5-methoxyphenyl)acrylic acid (11e). The
product 11e was obtained as a white solid (0.82 g, 92%); Mp
227–230 °C (decomposed); 1H NMR (400 MHz, DMSO-d6) δ
12.63 (br s, 1H), 7.84 (s, 1H), 7.23 (s, 1H), 6.95 (d, 1H, J = 12.2
Hz), 6.14 (d, 1H, J = 12.2 Hz), 3.81 (s, 3H); 13C NMR (100 MHz,
DMSO-d6) δ 166.4, 154.2, 139.6, 136.2, 134.8, 123.9, 114.3,
112.9, 111.3, 56.4; IR (neat) 2919, 2849, 1695, 1432, 1366, 1248,
1058, 872, 664 cm−1; HRMS (ESI) calcd for C10H9Br2O3
(M + H), 334.8918; found, 334.8911.
(E)-3-(2,4-Dibromo-5-methoxyphenyl)acrylic acid (11f). The
product 11f was obtained as a white solid (2.43 g, 96%); Mp
215–218 °C (decomposed); 1H NMR (400 MHz, DMSO-d6)
δ 12.73 (br s, 1H), 7.91 (s, 1H), 7.73 (d, 1H, J = 15.7 Hz), 7.51 (s,
1H), 6.78 (d, 1H, J = 15.7 Hz), 3.93 (s, 3H); 13C NMR (100 MHz,
DMSO-d6) δ 167.1, 155.2, 140.6, 135.9, 133.9, 123.3, 115.1,
113.7, 111.2, 56.8; IR (neat) 2848, 1690, 1625, 1469, 1369, 1210,
1054, 973, 699 cm−1; HRMS (ESI) calcd for C10H9Br2O3 (M +
H), 334.8918; found, 334.8910.
General procedure for the synthesis of Boc-protected
tetraamines 12a–c
To a cooled (0 °C) solution of diamine (11.8 mmol, 1.0 equiv.)
in anhydrous MeOH (5 mL) was added a solution of acrylo-
nitrile (1.25 g, 23.6 mmol, 2.0 equiv.) in anhydrous MeOH
(25 mL) dropwise over a period of 30 min. The resulting reac-
tion solution was allowed to warm to room temperature and
stirred for 22–24 h at room temperature. All volatiles were
removed under reduced pressure and the residue was purified
by silica gel column chromatography (10–40% MeOH–CHCl3)
to get both side Michael addition products.
To a cooled (0 °C) solution of the above obtained product
(11.8 mmol, 1.0 equiv.) in anhydrous MeOH (50 mL) was
added Et3N (2.61 g, 25.8 mmol, 2.2 equiv.) and then a solution
of Boc2O (5.38 g, 24.7 mmol, 2.1 equiv.) in anhydrous MeOH
(55 mL) was added dropwise. The resulting reaction solution
was allowed to warm to room temperature and stirred for 24 h
at room temperature. All volatiles were removed under reduced
pressure and the residue was purified by silica gel column
chromatography (30–60% EtOAc–hexane or 2% MeOH–
CH2Cl2) to get the Boc-protected compound.
To a solution of the above obtained Boc-protected com-
pound in a mixture of dioxane–water 4 : 1 (250 mL) were added
RANEY® nickel (7.5 g, 50% aqueous suspension), Pd/C
(250 mg) and lithium hydroxide monohydrate (940 mg,
22.4 mmol). The resulting solution was stirred at room temp-
erature under a hydrogen atmosphere for 2–10 h (monitored
by TLC). The reaction solution was filtered and washed with
MeOH (2 × 50 mL). The filtrate was concentrated under
reduced pressure and the residue was taken in CH2Cl2 (60 mL)
and water (60 mL). The organic layer was separated and
aqueous layer again extracted with CH2Cl2 (3 × 50 mL). The
combined organic layers were washed with brine, dried over
Na2SO4 and concentrated. The residue was pure enough to
proceed further or it can be purified by silica gel column
chromatography (2–10% Et3N–MeOH) to get the product.
General procedure for the synthesis of Boc-protected
tetraamines 13a–c
To a cooled (−78 °C) solution of appropriate amines 12a–c
(1.0 mmol, 1.0 equiv.) in anhydrous MeOH (16 mL) was added
CF3CO2Et (1.0 mmol, 1.0 equiv.) dropwise over a period of
10 min and stirred for 30 min at the same temperature. The
reaction solution was slowly allowed to warm to 0 °C. Then a
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solution of Boc2O (1.5 mmol, 1.5 equiv.) in MeOH (4 mL) was
added dropwise at 0 °C. The resulting reaction solution was
allowed to warm to room temperature and stirred for 10–15 h.
Then K2CO3 (5.0 mmol, 5.0 equiv.) and water (1.2 mL) were
added, and then the reaction solution was refluxed for 2–3 h.
After that, all volatiles were removed under reduced pressure
and the residue was taken in water (10 mL) and extracted with
CHCl3 (4 × 8 mL). The combined organic layers were washed
with brine, dried over Na2SO4 and concentrated to get the Boc-
protected tetraamines 13a–c.
(N1,N4,N11-Tri-tert-butyloxycarbonyl)-1,14-diamino-4,11-di-
azatetradecane 13c. The product 13c was obtained as a color-
less viscous liquid (1.14 g, 57%); 1H NMR (400 MHz, CDCl3)
δ 5.30 and 4.75 (br s, 1H), 3.23–3.08 (m, 10H), 2.72–2.68
(m, 2H), 2.38 (br s, 2H), 1.72–1.58 (m, 4H), 1.52–1.42 (m, 31H),
1.28–1.23 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 156.1, 155.5,
79.4, 78.9, 77.3, 50.4, 46.9, 44.1, 43.6, 39.4, 38.7, 37.4, 32.4,
30.9, 28.4, 28.3, 28.2, 26.6; IR (neat) 3356, 2975, 2931, 1678,
1417, 1249, 1156, 733 cm−1; HRMS (ESI) calcd for C27H55N4O6
(M + H), 531.4122; found, 531.4123.
General procedure for the synthesis of Boc-protected triamines
14a–c
To a cooled (0 °C) solution of an appropriate diamine
(34.9 mmol, 1.1 equiv.) in anhydrous MeOH (25 mL) was
added acrylonitrile (1.69 g, 31.8 mmol, 1.0 equiv.) dropwise
over a period of 2 h. The resulting reaction solution was
allowed to warm to room temperature and stirred for 22–24 h
at room temperature. All volatiles were removed under reduced
pressure and the residue was co-evaporated with anhydrous
toluene (3 × 25 mL).
In the case of 1,3-diaminopropane, all volatiles were
removed under reduced pressure and the residue was purified
by silica gel column chromatography (10–50% MeOH–CHCl3)
to get both side Michael addition products (618 mg, 36%) and
(10 : 90 : 1–40 : 60 : 1 MeOH–CHCl3–25% aqueous NH3) to get
one side Michael addition product (1.36 g, 57%).
To a cooled (0 °C) solution of the above obtained one side
Michael addition product (1.0 equiv.) in anhydrous CH2Cl2
(50 mL) was added Boc2O (13.0 g, 24.7 mmol, 2.1 equiv.) in
portions. The resulting solution was stirred for 10 min and
then ice was removed. i-Pr2NEt (11.0 mL, 25.8 mmol,
2.2 equiv.) was added dropwise over 1 h and then the reaction
mixture was stirred for 24 h at room temperature. All volatiles
were removed under reduced pressure and the residue was pur-
ified by silica gel column chromatography (30–60% EtOAc–
hexane) to get the Boc-protected compound.
To a cooled (0 °C) suspension of LiAlH4 (3.5 g, 93.0 mmol,
3.6 equiv.) in anhydrous Et2O (400 mL) was added a solution
of the above obtained Boc-protected compound (8.8 g,
25.8 mmol, 1.0 equiv.) in anhydrous Et2O (115 mL) dropwise
via cannula. The resulting reaction solution was allowed to
warm to room temperature and stirred for 7–16 h at room
temperature. The reaction was quenched by the dropwise
addition of NaOH (1.0 N aq. solution, 50 mL) at 0 °C, and then
it was filtered through a celite pad. The filtrate was washed
with brine, dried over Na2SO4 and concentrated. The residue
was purified by silica gel column chromatography
(3 : 96 : 1–10 : 89 : 1 MeOH–CH2Cl2–25% aqueous NH3) to get
the amine product (4.8 g, 54%).
{6-[(3-Amino-propyl)-tert-butoxycarbonyl-amino]-hexyl}-
carbamic acid tert-butyl ester 14c. The product 14c was
obtained as a colorless viscous liquid (3.16 g, 56%); 1H NMR
(400 MHz, CDCl3) δ 4.58 (br s, 1H), 3.26–3.06 (m, 6H), 2.94 (br
s, 2H), 2.71 (br s, 2H), 1.69 (br s, 2H), 1.51–1.43 (m, 4H), 1.41
(s, 9H), 1.40 (s, 9H), 1.33–1.19 (m, 4H); 13C NMR (100 MHz,
CDCl3) δ 156.2, 156.0, 155.5, 79.6, 79.3, 79.0, 77.3, 47.0, 46.6,
44.4, 43.6, 41.7, 40.4, 39.3, 38.4, 32.3, 30.3, 30.0, 28.43, 28.41,
28.0, 26.5; IR (neat) 3350, 2974, 2930, 2861, 1678, 1365, 1248,
1162, 871, 734 cm−1; HRMS (APCI) calcd for C19H40N3O4 (M +
H), 374.3019; found, 374.3019.
General procedure for amide synthesis
To a cooled (0 °C) solution of an appropriate α,β-unsaturated
carboxylic acid (0.42 mmol) in anhydrous CH2Cl2 (1.5 mL)
were added EDC·HCl (85 mg, 0.44 mmol) and HOBT (62 mg,
0.46 mmol). The resulting solution was stirred at 0 °C for
10 min, and then a solution of amine (0.2 mmol) in anhydrous
CH2Cl2 (1.5 mL) was added at 0 °C. The reaction solution was
allowed to warm to room temperature and stirred at room
temperature until complete consumption of the starting material
(monitored by TLC). CH2Cl2 (20 mL) was added and washed
with saturated aqueous NaHCO3 solution (3 mL), water (3 mL),
and brine (5 mL), dried over Na2SO4 and concentrated. The
residue was purified by silica gel column chromatography
(30–80% EtOAc–hexane) to get the coupled product.
Boc deprotection of the coupled product
To a cooled (0 °C) solution of the coupled product (obtained
above) in anhydrous CH2Cl2 (10 mL) was added TFA (1 mL).
The resulting solution was allowed to warm to room tempera-
ture until complete consumption of the starting material (∼1–3 h,
monitored by TLC). All volatiles were removed under reduced
pressure till dryness and then it was co-evaporated with
CH2Cl2 (3 × 15 mL) to get the white amorphous solid or the
residue was purified by silica gel column chromatography
(MeOH–CH2Cl2–TFA, 30 : 70 : 1–60 : 40 : 1).
Ianthelliformisamine A (1) tris-TFA salt
The product 1 was obtained as a white solid (118.2 mg, 68% in
two steps); Mp 206–209 °C (decomposed); 1H NMR (400 MHz,
DMSO-d6) δ 8.89 (br s, 2H), 8.74 (br s, 2H), 8.36 (t, 1H, J =
5.7 Hz), 8.02 (br s, 3H), 7.88 (s, 2H), 7.35 (d, 1H, J = 15.8 Hz),
6.68 (d, 1H, J = 15.8 Hz), 3.81 (s, 3H), 3.25 (q, 2H, J = 6.3 Hz),
2.98–2.92 (m, 10H), 1.90 (quintet, 2H, J = 7.6 Hz), 1.80
(quintet, 2H, J = 7.1 Hz), 1.69–1.57 (m, 4H); 13C NMR
(100 MHz, DMSO-d6) δ 164.8, 153.9, 135.3, 134.3, 131.5, 124.2,
118.0, 60.5, 46.1, 46.0, 44.6, 43.8, 36.1, 35.9, 25.9, 23.7, 22.6,
22.6; IR (neat) 3051, 2928, 2854, 1664, 1472, 1192, 1131, 978,
720 cm−1; HRMS (APCI) calcd for C20H33Br2N4O2 (M + H −
3TFA), 519.0970; found, 519.0955. HPLC purity 97.3%, RT =
15.100 min.
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Ianthelliformisamine B (2) bis-TFA salt
The product 2 was obtained as a colorless oil (114 mg, 74% in
two steps); 1H NMR (400 MHz, DMSO-d6) δ 8.68 (br s, 2H), 8.36
(t, 1H, J = 5.8 Hz), 7.91 (br s, 3H), 7.89 (s, 2H), 7.36 (d, 1H, J =
15.8 Hz), 6.69 (d, 1H, J = 15.8 Hz), 3.82 (s, 3H), 3.25 (q, 2H, J =
6.4 Hz), 2.93 (m, 4H), 2.85–2.80 (m, 2H), 1.84–1.77 (m, 2H),
1.62–1.60 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 164.8,
153.9, 135.4, 134.3, 131.5, 124.1, 118.0, 60.5, 46.0, 44.6, 38.2,
35.9, 25.9, 24.1, 22.5; IR (neat) 3390, 3068, 1671, 1425, 1182,
1135, 979, 723 cm−1; HRMS (ESI) calcd for C17H26Br2N3O2
(M + H − 2TFA), 462.0392; found, 462.0381. HPLC purity
100%, RT = 14.948 min.
Ianthelliformisamine C (3) bis-TFA salt
The product 3 was obtained as a colorless oil (199.3 mg, 75%
in two steps); 1H NMR (400 MHz, DMSO-d6) δ 8.78 (br s, 4H),
8.40 (t, 2H, J = 5.8 Hz), 7.89 (s, 4H), 7.35 (d, 2H, J = 15.8 Hz),
6.69 (d, 2H, J = 15.8 Hz), 3.81 (s, 6H), 3.25 (q, 4H, J = 6.4 Hz),
2.94 (m, 8H), 1.84–1.77 (m, 4H), 1.65 (m, 4H); 13C NMR
(100 MHz, DMSO-d6) δ 164.8, 153.9, 135.3, 134.3, 131.5, 124.2,
118.0, 60.5, 46.0, 44.6, 35.9, 25.9, 22.6; IR (neat) 3372, 3041,
2830, 1667, 1439, 1179, 1127, 977, 722 cm−1; HRMS (APCI)
calcd for C30H39Br4N4O4 (M + H − 2TFA), 834.9705; found,
834.9711. HPLC purity 100%, RT = 15.375 min.
(E)-N-(3-(4-(3-Aminopropylamino)butylamino)propyl)-3-(2,3,4-
tribromo-5-methoxyphenyl)acrylamide tris trifluoroacetate
15. The product 15 was obtained as a white solid (131.4 mg,
70% in two steps); Mp 214–218 °C (decomposed); 1H NMR
(400 MHz, DMSO-d6) δ 8.90 (br s, 2H), 8.75 (br s, 2H), 8.64 (t,
1H, J = 5.4 Hz), 8.03 (br s, 3H), 7.68 (d, 1H, J = 15.6 Hz), 7.37
(s, 1H), 6.82 (d, 1H, J = 15.6 Hz), 3.94 (s, 3H), 3.27 (q, 2H, J =
6.2 Hz), 2.93 (m, 10H), 1.90 (quintet, 2H, J = 7.6 Hz), 1.80
(quintet, 2H, J = 7.1 Hz), 1.64 (m, 4H); 13C NMR (100 MHz,
DMSO-d6) δ 164.5, 156.0, 137.6, 136.6, 129.1, 127.2, 117.7,
116.2, 109.5, 57.0, 46.1, 46.0, 44.7, 43.8, 36.1, 36.0, 25.9, 23.7,
22.6, 22.6; IR (neat) 3044, 2873, 1671, 1414, 1196, 1139, 837,
721 cm−1; HRMS (APCI) calcd for C20H32Br3N4O2 (M + H −
3TFA), 597.0075; found, 597.0060. HPLC purity 99.6%, RT =
14.833 min.
(E)-N-(3-(4-(3-Aminopropylamino)butylamino)propyl)-3-(2,4,6-
tribromo-3-methoxyphenyl)acrylamide tris trifluoroacetate
16. The product 16 was obtained as a white solid (137.3 mg,
73% in two steps); Mp 218–221 °C (decomposed); 1H NMR
(400 MHz, DMSO-d6) δ 8.58 (t, 1H, J = 5.7 Hz), 8.45 (br s, 6H),
8.10 (s, 1H), 7.28 (d, 1H, J = 16.0 Hz), 6.44 (d, 1H, J = 15.9 Hz),
3.81 (s, 3H), 3.29–3.26 (m, 2H), 2.98–2.87 (m, 10H), 1.90
(quintet, 2H, J = 7.6 Hz), 1.80 (quintet, 2H, J = 7.1 Hz), 1.64 (m,
4H); 13C NMR (100 MHz, DMSO-d6) δ 163.9, 153.6, 137.2,
136.5, 135.6, 130.3, 119.8, 117.8, 117.4, 60.3, 46.0, 46.0, 44.7,
43.8, 36.1, 25.8, 23.8, 22.6, 22.5; IR (neat) 3067, 2850, 1670,
1418, 1197, 1131, 835, 721 cm−1; HRMS (ESI) calcd for
C20H32Br3N4O2 (M + H − 3TFA), 597.0075; found, 597.0053.
HPLC purity 99.5%, RT = 14.788 min.
(E)-N-(3-(3-(3-Aminopropylamino)propylamino)propyl)-3-
(3,5-dibromo-4-methoxyphenyl)acrylamide tris trifluoroacetate
17. The product 17 was obtained as a white solid (301.4 mg,
89% in two steps); Mp 214–217 °C (decomposed); 1H NMR
(400 MHz, DMSO-d6) δ 9.01 (br s, 2H), 8.87 (br s, 2H), 8.38 (t,
1H, J = 5.7 Hz), 8.04 (br s, 3H), 7.88 (s, 2H), 7.35 (d, 1H, J =
15.8 Hz), 6.68 (d, 1H, J = 15.8 Hz), 3.81 (s, 3H), 3.28–3.23 (m,
2H), 2.99–2.90 (m, 10H), 1.97–1.89 (m, 4H); 1.82–1.78 (m, 2H);
13C NMR (100 MHz, DMSO-d6) δ 164.8, 153.9, 135.3, 134.3,
131.5, 124.2, 118.0, 60.5, 44.8, 44.0, 43.9, 36.1, 35.9, 27.9, 25.9,
23.8, 22.4; IR (neat) 3071, 2862, 1665, 1616, 1421, 1196, 1127,
987, 720 cm−1; HRMS (ESI) calcd for C19H31Br2N4O2 (M + H −
3TFA), 505.0814; found, 505.0812. HPLC purity 100%, RT =
16.045 min.
(E)-N-(3-(3-(3-Aminopropylamino)propylamino)propyl)-3-(2,3,
4-tribromo-5-methoxyphenyl)acrylamide tris trifluoroacetate
18. The product 18 was obtained as a white solid (136.5 mg,
74% in two steps); Mp 210–214 °C (decomposed); 1H NMR
(400 MHz, DMSO-d6) δ 8.97 (br s, 2H), 8.83 (br s, 2H), 8.62 (t,
1H, J = 5.7 Hz), 8.01 (br s, 3H), 7.68 (d, 1H, J = 15.6 Hz), 7.36
(s, 1H), 6.80 (d, 1H, J = 15.5 Hz), 3.94 (s, 3H), 3.30–3.25 (m,
2H), 2.99–2.88 (m, 10H), 1.97–1.88 (m, 4H); 1.83–1.80 (m, 2H);
13C NMR (100 MHz, DMSO-d6) δ 164.5, 156.0, 137.6, 136.6,
129.1, 127.2, 117.7, 116.2, 109.5, 57.0, 44.8, 44.0, 43.9, 36.1,
36.0, 25.9, 23.8, 22.4; IR (neat) 3074, 2942, 2869, 1667, 1422,
1367, 1197, 1161, 1132, 835, 721 cm−1; HRMS (APCI) calcd for
C19H30Br3N4O2 (M + H − 3TFA), 582.9919; found, 582.9893.
HPLC purity 98.1%, RT = 15.204 min.
(E)-N-(3-(3-(3-Aminopropylamino)propylamino)propyl)-3-(2,4,6-
tribromo-3-methoxyphenyl)acrylamide tris trifluoroacetate
19. The product 19 was obtained as a white solid (126.5 mg,
68% in two steps); Mp 228–231 °C (decomposed); 1H NMR
(400 MHz, DMSO-d6) δ 8.98 (br s, 2H), 8.85 (br s, 2H), 8.60 (t,
1H, J = 5.6 Hz), 8.11 (s, 1H), 8.02 (br s, 3H), 7.29 (d, 1H, J =
16.0 Hz), 6.45 (d, 1H, J = 16.0 Hz), 3.81 (s, 3H), 3.27 (q, 2H, J =
6.4 Hz), 3.00–2.89 (m, 10H), 2.00–1.87 (m, 4H); 1.86–1.79 (m,
2H); 13C NMR (100 MHz, DMSO-d6) δ 163.9, 153.6, 137.2,
136.5, 135.6, 130.3, 119.8, 117.9, 117.4, 60.3, 44.8, 44.0, 43.9,
36.1, 25.9, 23.8, 22.4; IR (neat) 3071, 2942, 2877, 1665, 1418,
1195, 1163, 835, 721 cm−1; HRMS (ESI) calcd for
C19H30Br3N4O2 (M + H − 3TFA), 582.9919; found, 582.9902.
HPLC purity 97.0%, RT = 15.426 min.
(E)-N-(3-(3-(3-Aminopropylamino)propylamino)propyl)-3-(2,4-
dibromo-5-methoxyphenyl)acrylamide tris trifluoroacetate
20. The product 20 was obtained as a white solid (119.8 mg,
71% in two steps); Mp 219–223 °C (decomposed); 1H NMR
(400 MHz, DMSO-d6) δ 8.97 (br s, 2H), 8.83 (br s, 2H), 8.59 (t,
1H, J = 5.7 Hz), 8.02 (br s, 3H), 7.92 (s, 1H), 7.60 (d, 1H, J =
15.6 Hz), 7.37 (s, 1H), 6.85 (d, 1H, J = 15.6 Hz), 3.92 (s, 3H),
3.27 (q, 2H, J = 6.4 Hz), 3.00–2.87 (m, 10H), 1.98–1.89 (m, 4H);
1.84–1.80 (m, 2H); 13C NMR (100 MHz, DMSO-d6) δ 164.7,
155.2, 136.0, 135.9, 134.8, 126.1, 114.8, 112.8, 110.5, 56.5, 44.8,
44.0, 43.9, 36.1, 36.0, 27.9, 25.9, 23.8, 22.4; IR (neat) 3068,
2876, 1666, 1465, 1195, 1128, 835, 720 cm−1; HRMS (ESI) calcd
for C19H31Br2N4O2 (M + H − 3TFA), 505.0814; found, 505.0813.
HPLC purity 99.9%, RT = 15.222 min.
(Z)-N-(3-(3-(3-Aminopropylamino)propylamino)propyl)-3-
(2,4-dibromo-5-methoxyphenyl)acrylamide tris trifluoroacetate
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21. The product 21 was obtained as a white solid (122.1 mg,
72% in two steps); Mp 220–223 °C (decomposed); 1H NMR
(400 MHz, DMSO-d6) δ 8.81 (br s, 4H), 8.42 (t, 1H, J = 5.6 Hz),
8.03 (br s, 3H), 7.81 (s, 1H), 7.36 (s, 1H), 6.74 (d, 1H, J =
12.2 Hz), 6.20 (d, 1H, J = 12.2 Hz), 3.79 (s, 3H), 3.14 (q, 2H, J =
6.4 Hz), 3.00–2.94 (m, 6H), 2.88 (t, 4H, J = 7.3 Hz), 1.95–1.89
(m, 4H); 1.76–1.72 (m, 2H); 13C NMR (100 MHz, DMSO-d6)
δ 164.9, 154.0, 136.3, 135.4, 134.7, 126.4, 114.5, 113.4, 110.9,
56.3, 44.8, 44.0, 43.9, 36.1, 35.7, 25.8, 23.8, 22.4; IR (neat)
3078, 2851, 1669, 1422, 1197, 1164, 835, 721 cm−1; HRMS (ESI)
calcd for C19H31Br2N4O2 (M + H − 3TFA), 505.0814; found,
505.0814. HPLC purity 99.8%, RT = 15.262 min.
(E)-N-(3-(6-(3-Aminopropylamino)hexylamino)propyl)-3-(3,5-
dibromo-4-methoxyphenyl)acrylamide tris trifluoroacetate
22. The product 22 was obtained as a white solid (292.4 mg,
82% in two steps); Mp 157–160 °C; 1H NMR (400 MHz, DMSO-
d6) δ 8.81 (br s, 2H), 8.65 (br s, 2H), 8.36 (t, 1H, J = 5.7 Hz),
8.05 (br s, 3H), 7.88 (s, 2H), 7.35 (d, 1H, J = 15.8 Hz), 6.68 (d,
1H, J = 15.8 Hz), 3.81 (s, 3H), 3.27–3.22 (m, 2H), 2.98–2.88 (m,
10H), 1.94–1.88 (m, 2H); 1.81–1.77 (m, 2H), 1.57 (m, 4H), 1.31
(m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 164.8, 153.9, 135.3,
134.3, 131.5, 124.2, 118.0, 60.5, 46.6, 44.7, 43.8, 36.1, 35.9,
25.9, 25.4, 25.3, 25.2, 23.7; IR (neat) 3048, 2935, 2866, 1687,
1420, 1195, 1138, 834, 720 cm−1; HRMS (APCI) calcd for
C22H37Br2N4O2 (M + H − 3TFA), 547.1283; found, 547.1272.
HPLC purity 99.3%, RT = 15.051 min.
N-(3-(6-(3-Aminopropylamino)hexylamino)propyl)-3-(2,3,4-tri-
bromo-5-methoxyphenyl)acrylamide tris trifluoroacetate 23.
The product 23 was obtained along with the Z-isomer (E : Z
ratio 5 : 1) as a white solid (155 mg, 80% in two steps); Mp
197–200 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.78 (br s, 2H),
8.60 and 8.45 (m and t, respectively, 3H, J = 5.4 Hz for t), 7.99
(br s, 3H), 7.68 and 6.82 (each d, 1H, J = 15.7 Hz and 11.9 Hz),
7.37 and 7.19 (each s, 1H), 6.80 and 6.18 (each d, 1H, J = 15.6
Hz and 11.7 Hz), 3.94 and 3.81 (each s, 3H), 3.27 and 3.13
(each q, 2H, J = 6.4 Hz), 2.97–2.86 (m, 10H), 1.90 (quintet, 2H,
J = 7.6 Hz); 1.81 and 1.71 (each quintet, 2H, J = 7.1 Hz and
7.0 Hz); 1.57 (m, 4H), 1.31 (m, 4H); 13C NMR (100 MHz,
DMSO-d6) δ 164.7, 164.5, 156.0, 155.1, 138.7, 137.6, 137.4,
136.6, 129.1, 127.6, 127.2, 126.1, 117.7, 116.2, 109.6, 57.0, 56.9,
46.6, 44.7, 43.8, 36.1, 36.0, 25.9, 25.5, 25.3, 25.2, 23.7; IR (neat)
3325, 3062, 2935, 2843, 1658, 1458, 1190, 1137, 837, 707 cm−1;
HRMS (ESI) calcd for C22H36Br3N4O2 (M + H − 3TFA),
625.0388; found, 625.0360. HPLC purity 99.3%, RT =
15.033 min.
(E)-N-(3-(6-(3-Aminopropylamino)hexylamino)propyl)-3-(2,4,6-
tribromo-3-methoxyphenyl)acrylamide tris trifluoroacetate 24.
The product 24 was obtained as a white solid (140.8 mg, 73%
in two steps); Mp 190–194 °C; 1H NMR (400 MHz, DMSO-d6)
δ 8.59 (t, 1H, J = 5.6 Hz), 8.52 (br s, 7H), 8.11 (s, 1H), 7.28 (d,
1H, J = 16.0 Hz), 6.45 (d, 1H, J = 16.0 Hz), 3.81 (s, 3H), 3.26 (q,
2H, J = 6.4 Hz), 3.01–2.86 (m, 10H), 1.95–1.87 (m, 2H);
1.86–1.80 (m, 2H), 1.58 (m, 4H), 1.32 (m, 4H); 13C NMR
(100 MHz, DMSO-d6) δ 163.9, 153.6, 137.3, 136.5, 135.6, 130.4,
119.8, 117.9, 117.4, 60.3, 46.6, 46.6, 44.7, 43.8, 36.1, 25.8, 25.5,
25.3, 25.2, 23.7; IR (neat) 3260, 2940, 2849, 1672, 1471, 1198,
1055, 836, 721 cm−1; HRMS (ESI) calcd for C22H36Br3N4O2 (M
+ H − 3TFA), 625.0388; found, 625.0360. HPLC purity 99.6%,
RT = 14.389 min.
N-(3-(6-(3-Aminopropylamino)hexylamino)propyl)-3-(2,4-
dibromo-5-methoxyphenyl)acrylamide tris trifluoroacetate 25.
The product 25 was obtained along with the Z-isomer (E : Z
ratio 9 : 1) as a white solid (120.3 mg, 68% in two steps); Mp
184–187 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.83 (br s, 2H),
8.68 (br s, 2H), 8.61 and 8.45 (each t, 1H, J = 5.6 Hz), 8.04 (br s,
3H), 7.92 and 7.81 (each s, 1H), 7.60 and 6.75 (each d, 1H, J =
15.6 Hz and 12.2 Hz), 7.38 and 7.34 (each s, 1H), 6.87 and 6.20
(each d, 1H, J = 15.6 Hz and 12. 2 Hz), 3.93 and 3.79 (each s,
3H), 3.27 and 3.14 (each q, 2H, J = 5.9 Hz), 2.98–2.89 (m, 10H),
1.90 (quintet, 2H, J = 7.6 Hz); 1.81 and 1.73 (each m, 2H), 1.58
(m, 4H), 1.32 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 165.0,
164.7, 155.2, 154.1, 136.0, 135.9, 134.8, 126.1, 114.8, 112.8,
110.6, 56.5, 56.4, 46.6, 44.7, 43.8, 36.1, 36.0, 25.9, 25.5, 25.3,
25.2, 23.7; IR (neat) 3064, 2937, 2866, 1667, 1467, 1193, 1056,
835, 720 cm−1; HRMS (ESI) calcd for C22H37Br2N4O2 (M + H −
3TFA), 547.1283; found, 547.1248. HPLC purity 100%, RT =
15.148 min.
(Z)-N-(3-(6-(3-Aminopropylamino)hexylamino)propyl)-3-(2,4-
dibromo-5-methoxyphenyl)acrylamide tris trifluoroacetate 26.
The product 26 was obtained as a white solid (117.2 mg, 66%
in two steps); Mp 157–160 °C; 1H NMR (400 MHz, DMSO-d6) δ
8.88 (br s, 2H), 8.68 (br s, 2H), 8.47 (t, 1H, J = 5.6 Hz), 8.07 (br
s, 3H), 7.82 (s, 1H), 7.35 (s, 1H), 6.75 (d, 1H, J = 12.2 Hz), 6.21
(d, 1H, J = 12.3 Hz), 3.80 (s, 3H), 3.14 (q, 2H, J = 6.4 Hz),
2.99–2.87 (m, 10H), 1.96–1.88 (m, 2H); 1.77–1.70 (m, 2H),
1.58–1.55 (m, 4H), 1.30 (m, 4H); 13C NMR (100 MHz, DMSO-
d6) δ 165.0, 154.1, 136.5, 135.6, 134.7, 126.4, 114.5, 113.4,
110.8, 56.4, 46.6, 44.6, 43.8, 36.1, 35.6, 25.8, 25.5, 25.3, 25.2,
23.7; IR (neat) 3065, 2937, 2867, 1667, 1471, 1194, 1056, 835,
720 cm−1; HRMS (ESI) calcd for C22H37Br2N4O2 (M + H −
3TFA), 547.1283; found, 547.1281. HPLC purity 100%, RT =
15.037 min.
(E)-N-(3-(4-Aminobutylamino)propyl)-3-(2,3,4-tribromo-
5-methoxyphenyl)acrylamide bis trifluoroacetate 27. The
product 27 was obtained as a white sticky solid (106.8 mg, 85%
in two steps); 1H NMR (400 MHz, DMSO-d6) δ 8.72 (br s, 2H),
8.64 (t, 1H, J = 5.9 Hz), 7.94 (br s, 3H), 7.68 (d, 1H, J = 15.6 Hz),
7.37 (s, 1H), 6.82 (d, 1H, J = 15.6 Hz), 3.94 (s, 3H), 3.29–3.24
(m, 2H), 2.93 (m, 4H), 2.84–2.79 (m, 2H), 1.85–1.77 (m, 2H),
1.61 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 164.5, 156.0,
137.6, 136.6, 129.1, 127.2, 117.7, 116.2, 109.5, 57.0, 46.0, 44.6,
38.1, 36.0, 25.9, 24.1, 22.5; IR (neat) 3395, 1661, 1048, 993,
762 cm−1; HRMS (ESI) calcd for C17H25Br3N3O2 (M + H −
2TFA), 539.9497; found, 539.9493. HPLC purity 100%, RT =
14.856 min.
(Z)-N-(3-(4-Aminobutylamino)propyl)-3-(2,3,4-tribromo-
5-methoxyphenyl)acrylamide bis trifluoroacetate 28. The
product 28 was obtained as a white solid (60.1 mg, 78% in two
steps); Mp 138–140 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.70
(br s, 2H), 8.46 (t, 1H, J = 5.6 Hz), 7.95 (br s, 3H), 7.20 (s, 1H),
6.81 (d, 1H, J = 12.2 Hz), 6.18 (d, 1H, J = 12.2 Hz), 3.81 (s, 3H),
3.14–3.09 (m, 2H), 2.87–2.79 (m, 6H), 1.75–1.68 (m, 2H),
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1.59–1.57 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 164.6,
155.0, 138.6, 137.2, 127.6, 126.2, 115.9, 114.1, 113.0, 56.9, 46.1,
44.6, 38.2, 35.7, 25.9, 24.1, 22.5; IR (neat) 3289, 3027, 2841,
1670, 1558, 1186, 1129, 841, 722 cm−1; HRMS (APCI) calcd for
C17H25Br3N3O2 (M + H − 2TFA), 539.9497; found, 539.9500.
HPLC purity 100%, RT = 15.230 min.
(E)-N-(3-(4-Aminobutylamino)propyl)-3-(2,4,6-tribromo-3-
methoxyphenyl)acrylamide bis trifluoroacetate 29. The
product 29 was obtained as a white solid (134.3 mg, 78% in
two steps); Mp 182–185 °C; 1H NMR (400 MHz, DMSO-d6)
δ 8.75 (br s, 2H), 8.61 (t, 1H, J = 5.7 Hz), 8.10 (s, 1H), 7.96 (br s,
3H), 7.28 (d, 1H, J = 15.9 Hz), 6.44 (d, 1H, J = 16.0 Hz), 3.80 (s,
3H), 3.26 (q, 2H, J = 6.4 Hz), 2.93 (m, 4H), 2.82–2.81 (m, 2H),
1.85–1.78 (m, 2H), 1.61 (m, 4H); 13C NMR (100 MHz, DMSO-
d6) δ 163.9, 153.6, 137.3, 136.5, 135.6, 130.3, 119.8, 117.9,
117.4, 60.3, 46.0, 44.6, 38.1, 36.1, 25.8, 24.1, 22.5; IR (neat)
3419, 3235, 3066, 2879, 1662, 1352, 1174, 1044, 949, 718 cm−1;
HRMS (ESI) calcd for C17H25Br3N3O2 (M + H − 2TFA),
539.9497; found, 539.9487. HPLC purity 99.5%, RT =
15.376 min.
(E)-N-(3-(4-Aminobutylamino)propyl)-3-(2,4-dibromo-5-meth-
oxyphenyl)acrylamide bis trifluoroacetate 30. The product 30
was obtained as a white sticky solid (129.5 mg, 84% in two
steps); 1H NMR (400 MHz, DMSO-d6) δ 8.75 (br s, 2H), 8.62 (t,
1H, J = 5.7 Hz), 7.96 (br s, 3H), 7.91 (s, 1H), 7.60 (d, 1H, J =
15.6 Hz), 7.38 (s, 1H), 6.88 (d, 1H, J = 15.6 Hz), 3.92 (s, 3H),
3.27 (q, 2H, J = 6.3 Hz), 2.94 (m, 4H), 2.85–2.80 (m, 2H),
1.86–1.79 (m, 2H), 1.66–1.59 (m, 4H); 13C NMR (100 MHz,
DMSO-d6) δ 164.7, 155.2, 136.0, 135.9, 134.8, 126.1, 114.8,
112.8, 110.6, 56.5, 46.0, 44.7, 38.1, 36.0, 25.9, 24.1, 22.5; IR
(neat) 3276, 3029, 2850, 1673, 1468, 1179, 1129, 1056, 970,
723 cm−1; HRMS (ESI) calcd for C17H26Br2N3O2 (M + H −
2TFA), 462.0392; found, 462.0381. HPLC purity 99.9%, RT =
14.924 min.
(Z)-N-(3-(4-Aminobutylamino)propyl)-3-(2,4-dibromo-5-meth-
oxyphenyl)acrylamide bis trifluoroacetate 31. The product 31
was obtained as a white solid (103.6 mg, 75% in two steps);
Mp 114–117 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.70 (br s,
2H), 8.44 (t, 1H, J = 5.6 Hz), 7.95 (br s, 3H), 7.81 (s, 1H), 7.35
(s, 1H), 6.74 (d, 1H, J = 12.2 Hz), 6.20 (d, 1H, J = 12.2 Hz), 3.79
(s, 3H), 3.16–3.11 (m, 2H), 2.87–2.80 (m, 6H), 1.77–1.70 (m,
2H), 1.60–1.58 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 164.9,
154.0, 136.4, 135.4, 134.7, 126.4, 114.5, 113.4, 110.9, 56.4, 46.0,
44.6, 38.1, 35.7, 25.8, 24.1, 22.5; IR (neat) 3399, 3064, 1672,
1196, 1130, 838, 720 cm−1; HRMS (ESI) calcd for
C17H26Br2N3O2 (M + H − 2TFA), 462.0392; found, 462.0366.
HPLC purity 99.1%, RT = 15.198 min.
(E)-N-(3-(3-Aminopropylamino)propyl)-3-(3,5-dibromo-4-meth-
oxyphenyl)acrylamide bis trifluoroacetate 32. The product 32
was obtained as a white solid (239 mg, 88% in two steps); Mp
119–121 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.81 (br s, 2H),
8.38 (t, 1H, J = 5.6 Hz), 8.03 (br s, 3H), 7.88 (s, 2H), 7.35 (d, 1H,
J = 15.6 Hz), 6.68 (d, 1H, J = 15.6 Hz), 3.81 (s, 3H), 3.25 (q, 2H,
J = 6.4 Hz), 3.00–2.91 (m, 6H), 1.94–1.86 (m, 2H), 1.83–1.76 (m,
2H); 13C NMR (100 MHz, DMSO-d6) δ 164.8, 153.9, 135.4,
134.3, 131.5, 124.1, 118.0, 60.5, 44.8, 43.9, 36.1, 35.9, 25.9,
23.8; IR (neat) 3037, 2930, 1666, 1264, 1166, 1132, 975,
721 cm−1; HRMS (APCI) calcd for C16H24Br2N3O2 (M + H −
2TFA), 448.0235; found, 448.0237. HPLC purity 100%, RT =
14.913 min.
(E)-N-(3-(3-Aminopropylamino)propyl)-3-(2,3,4-tribromo-5-
methoxyphenyl)acrylamide bis trifluoroacetate 33. The
product 33 was obtained as a white solid (135.5 mg, 90% in
two steps); Mp 170–173 °C; 1H NMR (400 MHz, DMSO-d6) δ
8.76 (br s, 2H), 8.61 (t, 1H, J = 5.6 Hz), 7.98 (br s, 3H), 7.68 (d,
1H, J = 15.6 Hz), 7.36 (s, 1H), 6.80 (d, 1H, J = 15.6 Hz), 3.94 (s,
3H), 3.27 (q, 2H, J = 6.4 Hz), 3.00–2.87 (m, 6H), 1.94–1.86 (m,
2H), 1.83–1.78 (m, 2H); 13C NMR (100 MHz, DMSO-d6) δ 164.5,
156.0, 137.6, 136.6, 129.1, 127.2, 117.7, 116.2, 109.5, 57.0, 44.8,
43.9, 36.1, 36.0, 25.9, 23.8; IR (neat) 3038, 2848, 1670, 1568,
1368, 1139, 969, 723 cm−1; HRMS (APCI) calcd for
C16H23Br3N3O2 (M + H − 2TFA), 525.9340; found, 525.9339.
HPLC purity 97.3%, RT = 15.100 min. HPLC purity 100%, RT =
14.825 min.
(E)-N-(3-(3-Aminopropylamino)propyl)-3-(2,4,6-tribromo-3-
methoxyphenyl)acrylamide bis trifluoroacetate 34. The
product 34 was obtained as a white solid (284.9 mg, 94% in
two steps); Mp 208–210 °C (decomposed); 1H NMR (400 MHz,
DMSO-d6) δ 8.77 (br s, 2H), 8.59 (t, 1H, J = 5.6 Hz), 8.10 (s, 1H),
7.99 (br s, 3H), 7.28 (d, 1H, J = 16.1 Hz), 6.44 (d, 1H, J =
16.1 Hz), 3.81 (s, 3H), 3.29–3.24 (m, 2H), 3.00–2.89 (m, 6H),
1.93–1.86 (m, 2H), 1.85–1.79 (m, 2H); 13C NMR (100 MHz,
DMSO-d6) δ 163.9, 153.6, 137.2, 136.5, 135.6, 130.3, 119.8,
117.9, 117.4, 60.3, 44.8, 43.9, 36.1, 36.1, 25.9, 23.8; IR (neat)
3062, 2932, 1671, 1351, 1173, 1131, 968, 720 cm−1; HRMS
(APCI) calcd for C16H23Br3N3O2 (M + H − 2TFA), 525.9340;
found, 525.9341. HPLC purity 99.6%, RT = 15.124 min.
(E)-N-(3-(3-Aminopropylamino)propyl)-3-(2,4-dibromo-5-meth-
oxyphenyl)acrylamide bis trifluoroacetate 35. The product 35
was obtained along with the Z-isomer (E : Z ratio 18 : 1) as a
white solid (112.5 mg, 83% in two steps); Mp 174–177 °C; 1H
NMR (400 MHz, DMSO-d6) δ 8.76 (br s, 2H), 8.58 and 8.42
(each t, 1H, J = 5.6 Hz), 7.99 (br s, 3H), 7.91 and 7.81 (each s,
1H), 7.59 and 6.74 (each d, 1H, J = 15.6 Hz and 12.2 Hz), 7.37
and 7.36 (each s, 1H), 6.85 and 6.20 (each d, 1H, J = 15.6 Hz
and 12.2 Hz), 3.92 and 3.79 (each s, 3H), 3.27 and 3.14 (each q,
2H, J = 6.4 Hz), 3.00–2.89 (m, 6H), 1.94–1.87 (m, 2H), 1.85–1.78
(m, 2H); 13C NMR (100 MHz, DMSO-d6) δ 164.7, 155.2, 136.0,
135.9, 134.8, 126.1, 114.8, 112.8, 110.6, 56.5, 44.8, 43.9, 36.1,
36.0, 25.9, 23.8; IR (neat) 3278, 3066, 2850, 1671, 1464, 1131,
970, 722 cm−1; HRMS (ESI) calcd for C16H24Br2N3O2 (M + H −
2TFA), 448.0235; found, 448.0218. HPLC purity 99.8%, RT =
15.510 min.
(Z)-N-(3-(3-Aminopropylamino)propyl)-3-(2,4-dibromo-5-meth-
oxyphenyl)acrylamide bis trifluoroacetate 36. The product 36
was obtained along with the E-isomer (Z : E ratio 15 : 1) as a
white solid (111.6 mg, 83% in two steps); Mp 154–157 °C; 1H
NMR (400 MHz, DMSO-d6) δ 8.80 (br s, 2H), 8.44 and 8.61
(each t, 1H, J = 5.6 Hz), 8.03 (br s, 3H), 7.81 and 7.91 (each s,
1H), 7.36 and 7.37 (each s, 1H), 6.74 and 7.59 (each d, 1H, J =
12.2 Hz and 15.6 Hz), 6.20 and 6.86 (each d, 1H, J = 12.3 Hz
and 15.7 Hz), 3.79 and 3.92 (each s, 3H), 3.14 and 3.27 (each q,
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2H, J = 6.4 Hz), 2.95–2.87 (m, 6H), 1.92–1.85 (m, 2H), 1.77–1.70
(m, 2H); 13C NMR (100 MHz, DMSO-d6) δ 164.9, 154.1, 136.3,
135.4, 134.7, 126.4, 114.6, 113.4, 110.9, 56.4, 44.8, 43.9, 36.1,
35.7, 25.8, 23.8; IR (neat) 3264, 3065, 2848, 1671, 1467, 1169,
1056, 722 cm−1; HRMS (ESI) calcd for C16H24Br2N3O2 (M + H −
2TFA), 448.0235; found, 448.0220. HPLC purity 100%, RT =
15.841 min.
(E)-N-(3-(6-Aminohexylamino)propyl)-3-(3,5-dibromo-4-meth-
oxyphenyl)acrylamide bis trifluoroacetate 37. The product 37
was obtained as a colorless oil (118.3 mg, 82% in two steps);
1H NMR (400 MHz, DMSO-d6) δ 8.68 (br s, 2H), 8.38 (t, 1H, J =
5.8 Hz), 7.89 (s, 5H, br s merged with s of aromatic H), 7.35 (d,
1H, J = 15.7 Hz), 6.70 (d, 1H, J = 15.7 Hz), 3.82 (s, 3H), 3.26 (q,
2H, J = 6.4 Hz), 2.93–2.86 (m, 4H), 2.81–2.75 (m, 2H), 1.82–1.79
(m, 2H), 1.57–1.52 (m, 4H), 1.33–1.31 (m, 4H); 13C NMR
(100 MHz, DMSO-d6) δ 164.8, 153.9, 135.3, 134.3, 131.5, 124.2,
118.0, 60.5, 46.6, 44.7, 38.6, 35.9, 26.7, 25.9, 25.4, 25.3; IR
(neat) 2948, 2867, 1668, 1472, 1131, 977, 722 cm−1; HRMS
(ESI) calcd for C19H30Br2N3O2 (M + H − 2TFA), 490.0705;
found, 490.0697. HPLC purity 100%, RT = 15.130 min.
(E)-N-(3-(6-Aminohexylamino)propyl)-3-(2,3,4-tribromo-5-meth-
oxyphenyl)acrylamide bis trifluoroacetate 38. The product 38
was obtained as a white solid (105 mg, 66% in two steps); Mp
98–100 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.62 (t, 3H, J =
5.4 Hz), 7.85 (br s, 3H), 7.68 (d, 1H, J = 15.6 Hz), 7.37 (s, 1H),
6.80 (d, 1H, J = 15.7 Hz), 3.94 (s, 3H), 3.27 (q, 2H, J = 6.4 Hz),
2.93–2.86 (m, 4H), 2.80–2.75 (m, 2H), 1.83–1.78 (m, 2H),
1.57–1.51 (m, 4H), 1.31 (m, 4H); 13C NMR (100 MHz, DMSO-
d6) δ 164.5, 156.1, 137.6, 136.6, 129.1, 127.2, 117.7, 116.2,
109.6, 57.0, 46.7, 44.7, 38.6, 36.1, 26.8, 25.9, 25.4, 25.3; IR
(neat) 3335, 3057, 2965, 2860, 1691, 1542, 1361, 1182, 1128,
974, 799 cm−1; HRMS (APCI) calcd for C19H29Br3N3O2 (M + H
− 2TFA), 567.9810; found, 567.9824. HPLC purity 100%, RT =
15.376 min.
(Z)-N-(3-(6-Aminohexylamino)propyl)-3-(2,3,4-tribromo-5-meth-
oxyphenyl)acrylamide bis trifluoroacetate 39. The product 39
was obtained as a white sticky solid (50.2 mg, 63% in two
steps); 1H NMR (400 MHz, DMSO-d6) δ 8.67 (br s, 2H), 8.50 (t,
1H, J = 5.4 Hz), 7.92 (br s, 3H), 7.19 (s, 1H), 6.81 (d, 1H, J =
11.7 Hz), 6.19 (d, 1H, J = 11.7 Hz), 3.81 (s, 3H), 3.12 (q, 2H, J =
6.4 Hz), 2.83–2.76 (m, 6H), 1.72 (quintet, 2H, J = 7.0 Hz), 1.52
(m, 4H), 1.29–1.28 (m, 4H); 13C NMR (100 MHz, DMSO-d6)
δ 164.7, 155.1, 138.7, 137.4, 127.6, 126.2, 115.8, 114.0, 113.0,
56.9, 47.0, 44.6, 38.6, 35.6, 26.8, 25.9, 25.4, 25.3, 25.3; IR (neat)
3416, 3055, 2942, 2866, 1670, 1435, 1194, 1131, 839, 721 cm−1;
HRMS (ESI) calcd for C19H29Br3N3O2 (M + H − 2TFA),
567.9810; found, 567.9810. HPLC purity 99.7%, RT =
15.214 min.
(E)-N-(3-(6-Aminohexylamino)propyl)-3-(2,4,6-tribromo-3-meth-
oxyphenyl)acrylamide bis trifluoroacetate 40. The product 40
was obtained as a white sticky solid (117.8 mg, 74% in two
steps); 1H NMR (400 MHz, DMSO-d6) δ 8.87 (br s, 2H), 8.67 (t,
1H, J = 5.6 Hz), 8.09 (s, 1H), 7.98 (br s, 3H), 7.27 (d, 1H, J =
16.1 Hz), 6.45 (d, 1H, J = 16.1 Hz), 3.80 (s, 3H), 3.26 (q, 2H, J =
6.4 Hz), 2.91–2.89 (m, 4H), 2.79–2.74 (m, 2H), 1.86–1.79 (m,
2H), 1.59–1.54 (m, 4H), 1.31 (m, 4H); 13C NMR (100 MHz,
DMSO-d6) δ 163.9, 153.7, 137.3, 136.5, 135.6, 130.4, 119.9,
117.9, 117.4, 60.3, 46.6, 44.7, 38.6, 36.2, 26.8, 25.8, 25.5, 25.3,
25.3; IR (neat) 3397, 3078, 1673, 1444, 1202, 1133, 843,
724 cm−1; HRMS (ESI) calcd for C19H29Br3N3O2 (M + H −
2TFA), 567.9810; found, 567.9815. HPLC purity 99.7%, RT =
14.937 min.
(E)-N-(3-(6-Aminohexylamino)propyl)-3-(2,4-dibromo-5-meth-
oxyphenyl)acrylamide bis trifluoroacetate 41. The product 41
was obtained as a white solid (165.5 mg, 77% in two steps);
Mp 128–130 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.58
(t merged with br s, 3H, J = 5.9 Hz), 7.91 (s, 1H), 7.84 (br s,
3H), 7.59 (d, 1H, J = 15.6 Hz), 7.36 (s, 1H), 6.84 (d, 1H, J =
15.6 Hz), 3.92 (s, 3H), 3.27 (q, 2H, J = 6.2 Hz), 2.92–2.90 (m,
4H), 2.80–2.75 (m, 2H), 1.84–1.77 (m, 2H), 1.56–1.53 (m, 4H),
1.31 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 164.7, 155.2,
136.0, 135.9, 134.8, 126.1, 114.8, 112.8, 110.5, 56.5, 46.6, 44.7,
38.6, 36.0, 26.8, 25.9, 25.4, 25.3; IR (neat) 3255, 2939, 2852,
1667, 1462, 1129, 1056, 836, 721 cm−1; HRMS (ESI) calcd for
C19H30Br2N3O2 (M + H − 2TFA), 490.0705; found, 490.0703.
HPLC purity 99.9%, RT = 15.030 min.
(Z)-N-(3-(6-Aminohexylamino)propyl)-3-(2,4-dibromo-5-meth-
oxyphenyl)acrylamide bis trifluoroacetate 42. The product 42
was obtained as a white sticky solid (113.8 mg, 79% in two
steps); 1H NMR (400 MHz, DMSO-d6) δ 8.64 (br s, 2H), 8.46 (t,
1H, J = 5.6 Hz), 7.90 (br s, 3H), 7.81 (s, 1H), 7.34 (s, 1H), 6.75
(d, 1H, J = 12.2 Hz), 6.20 (d, 1H, J = 12.2 Hz), 3.79 (s, 3H), 3.14
(q, 2H, J = 6.4 Hz), 2.84–2.75 (m, 6H), 1.73 (quintet, 2H, J = 7.1
Hz), 1.55–1.52 (m, 4H), 1.30–1.29 (m, 4H); 13C NMR (100 MHz,
DMSO-d6) δ 165.0, 154.1, 136.5, 135.6, 134.7, 126.4, 114.5,
113.4, 110.8, 56.4, 46.6, 44.6, 38.6, 35.6, 26.8, 25.8, 25.4, 25.3,
25.3; IR (neat) 3283, 2946, 2845, 1677, 1465, 1126, 1054, 840,
722 cm−1; HRMS (ESI) calcd for C19H30Br2N3O2 (M + H −
2TFA), 490.0705; found, 490.0705. HPLC purity 100%, RT =
15.115 min.
(2E,2′E)-N,N′-(3,3′-(Butane-1,4-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,3,4-tribromo-5-methoxyphenyl)acrylamide) bis
trifluoroacetate 43. The product 43 was obtained as a white
sticky solid (103.6 mg, 85% in two steps); 1H NMR (400 MHz,
DMSO-d6) δ 8.76 (br s, 4H), 8.64 (t, 2H, J = 5.6 Hz), 7.68 (d, 2H,
J = 15.7 Hz), 7.37 (s, 2H), 6.82 (d, 2H, J = 15.2 Hz), 3.94 (s, 6H),
3.28–3.26 (m, 4H), 2.94 (m, 8H), 1.83–1.80 (m, 4H), 1.64 (m,
4H); 13C NMR (100 MHz, DMSO-d6) δ 164.5, 156.0, 137.6,
136.6, 129.1, 127.2, 117.7, 116.2, 109.5, 57.0, 46.0, 44.7, 36.0,
25.9, 22.6; IR (neat) 3403, 3068, 2848, 1667, 1413, 1193, 1129,
835, 718 cm−1; HRMS (ESI) calcd for C30H37Br6N4O4 (M + H −
2TFA), 990.7915; found, 990.7904. HPLC purity 100%, RT =
15.119 min.
(2Z,2′Z)-N,N′-(3,3′-(Butane-1,4-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,3,4-tribromo-5-methoxyphenyl)acrylamide) bis
trifluoroacetate 44. The product 44 was obtained as a white
solid (89.3 mg, 73% in two steps); Mp 160–162 °C; 1H NMR
(400 MHz, DMSO-d6) δ 8.79 (br s, 4H), 8.48 (t, 2H, J = 5.6 Hz),
7.19 (s, 2H), 6.80 (d, 2H, J = 12.2 Hz), 6.18 (d, 2H, J = 12.2 Hz),
3.80 (s, 6H), 3.12 (q, 4H, J = 6.4 Hz), 2.86 (m, 8H), 1.72
(quintet, 4H, J = 7.0 Hz), 1.59 (m, 4H); 13C NMR (100 MHz,
DMSO-d6) δ 164.6, 155.1, 138.7, 137.3, 127.6, 126.2, 115.9,
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114.1, 113.1, 56.9, 46.1, 44.6, 35.7, 25.9, 22.6; IR (neat) 3264,
3078, 2839, 1670, 1532, 1129, 1066, 842, 723 cm−1; HRMS
(APCI) calcd for C30H37Br6N4O4 (M + H − 2TFA), 990.7915;
found, 990.7933. HPLC purity 99.5%, RT = 15.137 min.
(2E,2′E)-N,N′-(3,3′-(Butane-1,4-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,4,6-tribromo-3-methoxyphenyl)acrylamide) bis
trifluoroacetate 45. The product 45 was obtained as a white
solid (135.6 mg, 89% in two steps); Mp 190–193 °C (decom-
posed); 1H NMR (400 MHz, DMSO-d6) δ 8.74 (br s, 4H), 8.60 (t,
2H, J = 5.6 Hz), 8.09 (s, 2H), 7.28 (d, 2H, J = 16.1 Hz), 6.44 (d,
2H, J = 15.7 Hz), 3.81 (s, 6H), 3.26 (q, 4H, J = 6.4 Hz), 2.94 (m,
8H), 1.82 (quintet, 4H, J = 7.1 Hz), 1.64 (m, 4H); 13C NMR
(100 MHz, DMSO-d6) δ 163.9, 153.6, 137.2, 136.5, 135.6, 130.3,
119.8, 117.9, 117.4, 60.3, 46.0, 44.7, 36.1, 25.8, 22.6; IR (neat)
3397, 3235, 3065, 1673, 1415, 1194, 1133, 965, 720 cm−1;
HRMS (ESI) calcd for C30H37Br6N4O4 (M + H − 2TFA),
990.7915; found, 990.7908. HPLC purity 100%, RT =
14.804 min.
(2E,2′E)-N,N′-(3,3′-(Butane-1,4-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,4-dibromo-5-methoxyphenyl)acrylamide) bis
trifluoroacetate 46. The product 46 was obtained as a white
sticky solid (116.7 mg, 88% in two steps); 1H NMR (400 MHz,
DMSO-d6) δ 8.80 (br s, 4H), 8.64 (t, 2H, J = 5.7 Hz), 7.90 (s, 2H),
7.59 (d, 2H, J = 15.6 Hz), 7.37 (s, 2H), 6.89 (d, 2H, J = 15.6 Hz),
3.92 (s, 6H), 3.27 (q, 4H, J = 6.3 Hz), 2.95 (m, 8H), 1.86–1.79
(m, 4H), 1.66 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 164.7,
155.2, 136.0, 135.8, 134.8, 126.2, 114.8, 112.8, 110.6, 56.5, 46.0,
44.7, 36.0, 25.9, 22.6; IR (neat) 3395, 1678, 1444, 1202, 1137,
846, 725 cm−1; HRMS (ESI) calcd for C30H39Br4N4O4 (M + H −
2TFA), 834.9705; found, 834.9703. HPLC purity 98.6%, RT =
15.775 min.
(2E,2′E)-N,N′-(3,3′-(Propane-1,3-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(3,5-dibromo-4-methoxyphenyl)acrylamide) bis tri-
fluoroacetate 47. The product 47 was obtained as a white solid
(174.1 mg, 83% in two steps); Mp 208–210 °C (decomposed);
1H NMR (400 MHz, DMSO-d6) δ 8.79 (br s, 4H), 8.35 (t, 2H, J =
5.6 Hz), 7.87 (s, 4H), 7.35 (d, 2H, J = 15.7 Hz), 6.67 (d, 2H, J =
15.7 Hz), 3.81 (s, 6H), 3.26 (q, 4H, J = 6.4 Hz), 3.00–2.94 (m,
8H), 1.95 (quintet, 2H, J = 7.3 Hz), 1.80 (quintet, 4H, J =
7.0 Hz); 13C NMR (100 MHz, DMSO-d6) δ 164.8, 153.9, 135.4,
134.3, 131.5, 124.1, 118.0, 60.5, 44.8, 43.9, 35.9, 26.0, 22.4; IR
(neat) 3082, 2865, 1664, 1472, 1196, 1132, 979, 743 cm−1;
HRMS (APCI) calcd for C29H37Br4N4O4 (M + H − 2TFA),
820.9548; found, 820.9547. HPLC purity 100%, RT =
14.648 min.
(2E,2′E)-N,N′-(3,3′-(Propane-1,3-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,3,4-tribromo-5-methoxyphenyl)acrylamide) bis
trifluoroacetate 48. The product 48 was obtained as a white
solid (94 mg, 77% in two steps); Mp 216–218 °C (decomposed);
1H NMR (400 MHz, DMSO-d6) δ 8.74 (br s, 4H), 8.59 (t, 2H, J =
5.6 Hz), 7.68 (d, 2H, J = 15.2 Hz), 7.35 (s, 2H), 6.77 (d, 2H, J =
15.7 Hz), 3.94 (s, 6H), 3.28 (q, 4H, J = 6.4 Hz), 3.00–2.95 (m,
8H), 1.98–1.93 (m, 2H), 1.85–1.79 (m, 4H); 13C NMR (100 MHz,
DMSO-d6) δ 164.5, 156.0, 137.7, 136.6, 129.1, 127.1, 117.7,
116.2, 109.5, 57.0, 44.8, 43.9, 36.0, 26.0, 22.5; IR (neat) 3278,
3077, 2862, 1665, 1367, 1197, 1134, 970, 719 cm−1; HRMS (ESI)
calcd for C29H35Br6N4O4 (M + H − 2TFA), 976.7759; found,
976.7781. HPLC purity 99.0%, RT = 15.191 min.
(2E,2′E)-N,N′-(3,3′-(Propane-1,3-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,4,6-tribromo-3-methoxyphenyl)acrylamide) bis
trifluoroacetate 49. The product 49 was obtained as a white
solid (195.4 mg, 81% in two steps); Mp 222–224 °C (decom-
posed); 1H NMR (400 MHz, DMSO-d6) δ 8.82 (br s, 4H), 8.60 (t,
2H, J = 5.4 Hz), 8.09 (s, 2H), 7.28 (d, 2H, J = 16.1 Hz), 6.44 (d,
2H, J = 16.1 Hz), 3.80 (s, 6H), 3.27 (q, 4H, J = 6.4 Hz), 3.01–2.95
(m, 8H), 1.99–1.92 (m, 2H), 1.82 (quintet, 4H, J = 7.1 Hz); 13C
NMR (100 MHz, DMSO-d6) δ 163.9, 153.6, 137.2, 136.5, 135.6,
130.3, 119.8, 117.9, 117.4, 60.3, 44.8, 43.9, 36.1, 25.9, 22.5; IR
(neat) 3253, 3072, 2869, 1665, 1558, 1196, 1135, 1043, 832,
718 cm−1; HRMS (APCI) calcd for C29H35Br6N4O4 (M + H −
2TFA), 976.7759; found, 976.7747. HPLC purity 100%, RT =
15.174 min.
(2E,2′E)-N,N′-(3,3′-(Hexane-1,6-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(3,5-dibromo-4-methoxyphenyl)acrylamide) bis
trifluoroacetate 50. The product 50 was obtained as a white
solid (184.3 mg, 84% in two steps); Mp 56–58 °C; 1H NMR
(400 MHz, DMSO-d6) δ 8.64 (br s, 4H), 8.36 (t, 2H, J = 5.6 Hz),
7.88 (s, 4H), 7.35 (d, 2H, J = 15.7 Hz), 6.68 (d, 2H, J = 16.1 Hz),
3.81 (s, 6H), 3.25 (q, 4H, J = 6.4 Hz), 2.92–2.89 (m, 8H), 1.79
(quintet, 4H, J = 7.1 Hz), 1.57 (m, 4H), 1.31 (m, 4H); 13C NMR
(100 MHz, DMSO-d6) δ 164.8, 153.9, 135.4, 134.3, 131.6, 124.2,
118.0, 115.2, 60.5, 46.6, 44.7, 36.0, 26.0, 25.4, 25.3; IR (neat)
3290, 2944, 2864, 1660, 1471, 1200, 1177, 1133, 982, 721 cm−1;
HRMS (APCI) calcd for C32H43Br4N4O4 (M + H − 2TFA),
863.0018; found, 863.0023. HPLC purity 100%, RT =
14.871 min.
(2E,2′E)-N,N′-(3,3′-(Hexane-1,6-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,3,4-tribromo-5-methoxyphenyl)acrylamide) bis
trifluoroacetate 51. The product 51 was obtained as a white
solid (101.3 mg, 81% in two steps); Mp 122–124 °C; 1H NMR
(400 MHz, DMSO-d6) δ 8.62 (m, 6H), 7.67 (d, 2H, J = 15.7 Hz),
7.36 (s, 2H), 6.80 (d, 2H, J = 15.2 Hz), 3.94 (s, 6H), 3.27 (m,
4H), 2.92–2.90 (m, 8H), 1.81 (quintet, 4H, J = 7.1 Hz), 1.57 (m,
4H), 1.31 (m, 4H); 13C NMR (100 MHz, DMSO-d6) δ 164.5,
156.0, 137.7, 136.6, 129.1, 127.2, 117.7, 116.2, 109.5, 57.0, 46.6,
44.7, 36.1, 25.9, 25.4, 25.3; IR (neat) 3326, 3062, 2842, 1657,
1361, 1188, 975, 707 cm−1; HRMS (ESI) calcd for
C32H41Br6N4O4 (M + H − 2TFA), 1018.8228; found, 1018.8222.
HPLC purity 100%, RT = 14.803 min.
(2Z,2′Z)-N,N′-(3,3′-(Hexane-1,6-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,3,4-tribromo-5-methoxyphenyl)acrylamide) bis
trifluoroacetate 52. The product 52 was obtained as a white
solid (108.7 mg, 87% in two steps); Mp 138–141 °C; 1H NMR
(400 MHz, DMSO-d6) δ 8.65 (br s, 4H), 8.49 (t, 2H, J = 5.9 Hz),
7.19 (s, 2H), 6.81 (d, 2H, J = 12.2 Hz), 6.19 (d, 2H, J = 12.2 Hz),
3.81 (s, 6H), 3.12 (q, 4H, J = 6.4 Hz), 2.84–2.81 (m, 8H), 1.72
(quintet, 4H, J = 7.0 Hz), 1.52 (m, 4H), 1.26 (m, 4H); 13C NMR
(100 MHz, DMSO-d6) δ 164.7, 155.1, 138.7, 137.4, 127.6, 126.1,
115.8, 114.0, 113.0, 56.9, 46.7, 44.6, 35.6, 25.9, 25.5, 25.3; IR
(neat) 3270, 3072, 2838, 1672, 1358, 1134, 839, 722 cm−1; HRMS
(APCI) calcd for C32H41Br6N4O4 (M + H − 2TFA), 1018.8228;
found, 1018.8204. HPLC purity 99.9%, RT = 15.304 min.
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(2E,2′E)-N,N′-(3,3′-(Hexane-1,6-diylbis(azanediyl))bis(propane-
3,1-diyl))bis(3-(2,4,6-tribromo-3-methoxyphenyl)acrylamide) bis
trifluoroacetate 53. The product 53 was obtained as a white
solid (220.4 mg, 88% in two steps); Mp 186–188 °C; 1H NMR
(400 MHz, DMSO-d6) δ 8.66 (br s, 4H), 8.60 (t, 2H, J = 5.6 Hz),
8.08 (s, 2H), 7.28 (d, 2H, J = 15.7 Hz), 6.44 (d, 2H, J = 15.6 Hz),
3.80 (s, 6H), 3.26 (q, 4H, J = 6.4 Hz), 2.92–2.90 (m, 8H), 1.81
(quintet, 4H, J = 7.1 Hz), 1.58 (m, 4H), 1.32 (m, 4H); 13C NMR
(100 MHz, DMSO-d6) δ 164.0, 153.7, 137.3, 136.5, 135.6, 130.4,
119.9, 117.9, 117.5, 60.3, 46.6, 44.7, 36.1, 25.9, 25.5, 25.3; IR
(neat) 3283, 3065, 2843, 1778, 1659, 1414, 1150, 970, 708 cm−1;
HRMS (ESI) calcd for C32H41Br6N4O4 (M + H − 2TFA),
1018.8228; found, 1018.8210. HPLC purity 99.8%, RT =
14.646 min.
Antibacterial activity test
Test-bacteria. The antibacterial activity of various com-
pounds was assessed against two bacterial species: Gram-posi-
tive Staphylococcus aureus ATCC 25923 and Gram-negative
Escherichia coli ATCC 25922, maintained at −70 °C.
Disc-diﬀusion assay. Overnight cultures of cells of either
Staphylococcus aureus or Escherichia coli were uniformly
smeared on to Luria broth agar medium (Hi-Media) in Petri
plates, and sterile discs (5 mm diameter) containing 50 μg of
the diﬀerent synthesized compounds dissolved in dimethyl
sulfoxide (DMSO) were placed on to these plates to allow each
compound to diﬀuse into the surrounding areas and inhibit
bacterial growth. Production of such zones of growth inhi-
bition would indicate sensitivity of the bacteria to the specific
compound. For each treatment, 3 replicates were maintained.
The plates were then incubated at 37 °C for 12 h and the size
of the resulting zone of inhibition, if any, was determined.
Determination of the Minimum Inhibitory Concentration
(MIC): For the determination of MIC, bacterial strains were
exposed to 10-fold dilution series of the compounds ranging
from 0.1 to 15 000 μM at 37 °C for 24 h. MIC was defined as
the lowest concentration of the agent that resulted in the zone
of growth inhibition in the disc diﬀusion assay.
Time-kill assay. To determine cell viability, a single bacterial
colony was inoculated into Luria broth. Following overnight
growth the bacterial cultures were diluted 1 : 100 and further
grown for 2 h to allow exponential growth. E. coli and S. aureus
cultures were then treated with serial dilution of each of the
compounds at 37 °C for 4 h. At times 0 and 4 h post-treatment,
10 μL cultures were withdrawn and spotted on to Luria broth
agar medium and grown overnight at 37 °C.
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